AstraZeneca plc’s (AZN) Neutral Rating Reaffirmed at Credit Suisse Group
Credit Suisse Group reiterated their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Monday, MarketBeat reports. Credit Suisse Group currently has a GBX 5,000 ($63.70) price target on the biopharmaceutical company’s stock.
A number of other brokerages also recently issued reports on AZN. Barclays PLC reaffirmed an overweight rating and set a GBX 6,000 ($76.44) price target on shares of AstraZeneca plc in a report on Monday, June 5th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of AstraZeneca plc in a report on Monday, June 5th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,700 ($72.62) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Liberum Capital reissued a buy rating and issued a GBX 5,500 ($70.07) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Kepler Capital Markets reissued a buy rating and issued a GBX 5,500 ($70.07) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of GBX 5,171.80 ($65.89).
AstraZeneca plc (LON AZN) traded up 1.48% during midday trading on Monday, reaching GBX 5423.00. The company’s stock had a trading volume of 642,574 shares. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market capitalization is GBX 68.66 billion. The stock’s 50-day moving average price is GBX 5,118.49 and its 200 day moving average price is GBX 4,699.54.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.